Skip to main content

4 Result(s)

within Article Remove this filter A. Patsouris Remove this filter

and

  1. No Access

    Article

    Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer

    Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody–drug conjugates (ADCs): Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd), ...

    F. Poumeaud, M. Morisseau, L. Cabel, A. Gonçalves, C. Rivier… in British Journal of Cancer (2024)

  2. No Access

    Article

    Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation

    Efficacy of endocrine therapy in HR+/HER2− metastatic breast cancer could differ depending on the presence of BRCA1/2 germline mutation.

    J.-S. Frenel, A. Lusque, S. Delaloge, J.-M. Ferrero… in British Journal of Cancer (2023)

  3. No Access

    Article

    Enrollment of older metastatic breast cancer patients in first-line clinical trials: 9-year experience of the large-scale real-life multicenter French ESME cohort

    Older cancer patients are underrepresented in clinical trials. We aimed to evaluate the enrollment of older women aged 70 years old (yo) or over with metastatic breast cancer (MBC) in clinical trials.

    M. Bringuier, M. Carton, C. Levy, A. Patsouris… in Breast Cancer Research and Treatment (2022)

  4. No Access

    Article

    Facteurs pronostiques et prédictifs de réponse aux immunothérapies (TILs, TAM)

    Un grand nombre de biomarqueurs est à l’étude afin de préciser le pronostic de la maladie tumorale, notamment en situation adjuvante où les facteurs clinicopathologiques classiques peuvent faire défaut. La nat...

    A. Patsouris, N. Bendriss-Vermare in Oncologie (2015)